메뉴 건너뛰기




Volumn 4, Issue 1, 2012, Pages 66-74

Hormonal resistance in breast cancer: Evolving treatment strategies

Author keywords

Breast cancer; Endocrine resistance; Everolimus; Hormonal resistance; mTOR

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MEGESTROL ACETATE; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROGESTERONE RECEPTOR; PUMA PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN; TAMOXIFEN; TRASTUZUMAB; VORINOSTAT;

EID: 84858707938     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-011-0065-1     Document Type: Review
Times cited : (2)

References (59)
  • 1
    • 79951592552 scopus 로고    scopus 로고
    • Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in breast cancer cells
    • Nassa G, Tarallo R, Guzzi PH, Ferraro L, Cirillo F, Ravo M et al. Comparative analysis of nuclear estrogen receptor alpha and beta interactomes in breast cancer cells. Mol BioSyst. 2010.
    • (2010) Mol BioSyst
    • Nassa, G.1    Tarallo, R.2    Guzzi, P.H.3    Ferraro, L.4    Cirillo, F.5    Ravo, M.6
  • 3
    • 11244296162 scopus 로고    scopus 로고
    • Mechanisms of tamoxifen resistance
    • Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocrine Relat Canc. 2004;11(4):643.
    • (2004) Endocrine Relat Canc , vol.11 , Issue.4 , pp. 643
    • Ring, A.1    Dowsett, M.2
  • 4
    • 0038688478 scopus 로고    scopus 로고
    • Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
    • Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21 (10):1973.
    • (2003) J Clin Oncol , vol.21 , Issue.10 , pp. 1973
    • Bardou, V.J.1    Arpino, G.2    Elledge, R.M.3    Osborne, C.K.4    Clark, G.M.5
  • 5
    • 54749118927 scopus 로고    scopus 로고
    • Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    • Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008;68 (18):7493.
    • (2008) Cancer Res , vol.68 , Issue.18 , pp. 7493
    • Creighton, C.J.1    Massarweh, S.2    Huang, S.3    Tsimelzon, A.4    Hilsenbeck, S.G.5    Osborne, C.K.6
  • 6
    • 79551576468 scopus 로고    scopus 로고
    • Mechanisms of endocrine resistance in breast cancer
    • Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
    • (2011) Annu Rev Med , vol.62 , pp. 233-247
    • Osborne, C.K.1    Schiff, R.2
  • 7
    • 79551510050 scopus 로고    scopus 로고
    • The need to examine metastatic tissue at the time of progression of breast cancer: Is re-biopsy a necessity or a luxury?
    • Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep. 2011;13(1):17-25.
    • (2011) Curr Oncol Rep , vol.13 , Issue.1 , pp. 17-25
    • Khasraw, M.1    Brogi, E.2    Seidman, A.D.3
  • 8
    • 77953198056 scopus 로고    scopus 로고
    • American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    • unabridged version
    • Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):48-72.
    • (2010) Arch Pathol Lab Med , vol.134 , Issue.7 , pp. 48-72
    • Hammond, M.E.H.1    Hayes, D.F.2    Dowsett, M.3    Allred, D.C.4    Hagerty, K.L.5    Badve, S.6
  • 9
    • 29144475553 scopus 로고    scopus 로고
    • Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials
    • Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366 (9503):2087.
    • (2005) Lancet , vol.366 , Issue.9503 , pp. 2087
    • Clarke, M.1    Collins, R.2    Darby, S.3    Davies, C.4    Elphinstone, P.5    Evans, E.6
  • 10
    • 78650513948 scopus 로고    scopus 로고
    • Estrogen Receptors: Their Actions and Functional Roles in Health and Disease; Nuclear Receptors
    • Bunce CM, Campbell MJ, editors. Netherlands: Springer
    • Nilsson S, Gustafsson J-Ö. Estrogen Receptors: Their Actions and Functional Roles in Health and Disease; Nuclear Receptors. In: Bunce CM, Campbell MJ, editors. Proteins and cell regulation, vol. 8. Netherlands: Springer; 2010. p. 91-141.
    • (2010) Proteins and Cell Regulation , vol.8 , pp. 91-141
    • Nilsson, S.1    Gustafsson, J.-Ö.2
  • 12
    • 73949145188 scopus 로고    scopus 로고
    • Expression of estrogen receptor β increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells
    • Lindberg K, Ström A, Lock JG, Gustafsson JÖ, Haldosén LA, Helguero LA. Expression of estrogen receptor β increases integrin α1 and integrin β1 levels and enhances adhesion of breast cancer cells. J Cell Physiol. 2010;222(1):156-67.
    • (2010) J Cell Physiol , vol.222 , Issue.1 , pp. 156-167
    • Lindberg, K.1    Ström, A.2    Lock, J.G.3    Gustafsson, J.Ö.4    Haldosén, L.A.5    Helguero, L.A.6
  • 13
    • 67349223542 scopus 로고    scopus 로고
    • Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications
    • Hartman J, Ström A, Gustafsson JÖ. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids. 2009;74(8):635-41.
    • (2009) Steroids , vol.74 , Issue.8 , pp. 635-641
    • Hartman, J.1    Ström, A.2    Gustafsson, J.Ö.3
  • 14
    • 0029759541 scopus 로고    scopus 로고
    • Annual hazard rates of recurrence for breast cancer after primary therapy
    • Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14 (10):2738.
    • (1996) J Clin Oncol , vol.14 , Issue.10 , pp. 2738
    • Saphner, T.1    Tormey, D.C.2    Gray, R.3
  • 15
    • 0035499267 scopus 로고    scopus 로고
    • Stem cells, cancer, and cancer stem cells
    • DOI 10.1038/35102167
    • Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-11. (Pubitemid 33041634)
    • (2001) Nature , vol.414 , Issue.6859 , pp. 105-111
    • Reya, T.1    Morrison, S.J.2    Clarke, M.F.3    Weissman, I.L.4
  • 16
    • 77954957349 scopus 로고    scopus 로고
    • Human breast cancer stem cells and sex hormones-a narrative review
    • Eden JA. Human breast cancer stem cells and sex hormones-a narrative review. Menopause. 2010;17(4):801.
    • (2010) Menopause , vol.17 , Issue.4 , pp. 801
    • Eden, J.A.1
  • 17
    • 8944237006 scopus 로고    scopus 로고
    • Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
    • Arimidex Study Group
    • Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000.
    • (1996) J Clin Oncol , vol.14 , Issue.7 , pp. 2000
    • Buzdar, A.1    Jonat, W.2    Howell, A.3    Jones, S.E.4    Blomqvist, C.5    Vogel, C.L.6
  • 18
    • 0031943424 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
    • Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453.
    • (1998) J Clin Oncol , vol.16 , Issue.2 , pp. 453
    • Dombernowsky, P.1    Smith, I.2    Falkson, G.3    Leonard, R.4    Panasci, L.5    Bellmunt, J.6
  • 19
    • 0034128928 scopus 로고    scopus 로고
    • Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
    • Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000;18(7):1399.
    • (2000) J Clin Oncol , vol.18 , Issue.7 , pp. 1399
    • Kaufmann, M.1    Bajetta, E.2    Dirix, L.Y.3    Fein, L.E.4    Jones, S.E.5    Zilembo, N.6
  • 20
    • 7344242595 scopus 로고    scopus 로고
    • Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
    • Gershanovich M, Chaudri H, Campos D, Lurie H, Bonaventura A, Jeffrey M, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998;9(6):639.
    • (1998) Ann Oncol , vol.9 , Issue.6 , pp. 639
    • Gershanovich, M.1    Chaudri, H.2    Campos, D.3    Lurie, H.4    Bonaventura, A.5    Jeffrey, M.6
  • 21
    • 0345596372 scopus 로고    scopus 로고
    • Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
    • DOI 10.1016/S0959-8049(97)00283-9, PII S0959804997002839
    • Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Eur J Cancer. 1997;33(11):1767-73. (Pubitemid 28129201)
    • (1997) European Journal of Cancer , vol.33 , Issue.11 , pp. 1767-1773
    • Thurlimann, B.1    Paridaens, R.2    Serin, D.3    Bonneterre, J.4    Roche, H.5    Murray, R.6    Di, S.E.7    Lanzalone, S.8    Zurlo, M.G.9    Piscitelli, G.10
  • 22
    • 17144472154 scopus 로고    scopus 로고
    • Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
    • Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234.
    • (2000) J Clin Oncol , vol.18 , Issue.11 , pp. 2234
    • Lonning, P.E.1    Bajetta, E.2    Murray, R.3    Tubiana-Hulin, M.4    Eisenberg, P.D.5    Mickiewicz, E.6
  • 23
    • 17444453765 scopus 로고    scopus 로고
    • Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women
    • DOI 10.1016/S0959-8049(03)00602-6
    • Thurlimann B, Robertson J, Nabholtz J, Buzdar A, Bonneterre J. Efficacy of tamoxifen following anastrozole (Arimidex) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer. 2003;39(16):2310-7. (Pubitemid 37214855)
    • (2003) European Journal of Cancer , vol.39 , Issue.16 , pp. 2310-2317
    • Thurlimann, B.1    Robertson, J.F.R.2    Nabholtz, J.M.3    Buzdar, A.4    Bonneterre, J.5
  • 24
    • 77950634822 scopus 로고    scopus 로고
    • Fulvestrant-a novel endocrine therapy for breast cancer
    • Johnston S, Cheung K. Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17(10):902-14.
    • (2010) Curr Med Chem , vol.17 , Issue.10 , pp. 902-914
    • Johnston, S.1    Cheung, K.2
  • 25
    • 74649086996 scopus 로고    scopus 로고
    • Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials
    • Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol/Hemat. 2010;73(3):220-7.
    • (2010) Crit Rev Oncol/Hemat , vol.73 , Issue.3 , pp. 220-227
    • Valachis, A.1    Mauri, D.2    Polyzos, N.P.3    Mavroudis, D.4    Georgoulias, V.5    Casazza, G.6
  • 26
    • 78049523306 scopus 로고    scopus 로고
    • Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
    • Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594.
    • (2010) J Clin Oncol , vol.28 , Issue.30 , pp. 4594
    • Di Leo, A.1    Jerusalem, G.2    Petruzelka, L.3    Torres, R.4    Bondarenko, I.N.5    Khasanov, R.6
  • 27
    • 0033058968 scopus 로고    scopus 로고
    • Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis
    • DOI 10.1023/A:1006185805079
    • Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Canc Res Treat. 1999;54(2):117-22. (Pubitemid 29295314)
    • (1999) Breast Cancer Research and Treatment , vol.54 , Issue.2 , pp. 117-122
    • Peethambaram, P.P.1    Ingle, J.N.2    Suman, V.J.3    Hartmann, L.C.4    Loprinzi, C.L.5
  • 28
    • 0019382847 scopus 로고
    • Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
    • Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304(1):16-21. (Pubitemid 11212892)
    • (1981) New England Journal of Medicine , vol.304 , Issue.1 , pp. 16-21
    • Ingle, J.N.1    Ahmann, D.L.2    Green, S.J.3
  • 29
    • 68949102467 scopus 로고    scopus 로고
    • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study
    • Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009;302(7):774-80.
    • (2009) JAMA , vol.302 , Issue.7 , pp. 774-780
    • Ellis, M.J.1    Gao, F.2    Dehdashti, F.3    Jeffe, D.B.4    Marcom, P.K.5    Carey, L.A.6
  • 30
    • 41949104971 scopus 로고    scopus 로고
    • Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
    • Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008;26(7):1059.
    • (2008) J Clin Oncol , vol.26 , Issue.7 , pp. 1059
    • Dowsett, M.1    Allred, C.2    Knox, J.3    Quinn, E.4    Salter, J.5    Wale, C.6
  • 31
    • 37549056583 scopus 로고    scopus 로고
    • Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1-98 randomised trial
    • Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9(1):23-8.
    • (2008) Lancet Oncol , vol.9 , Issue.1 , pp. 23-28
    • Rasmussen, B.B.1    Regan, M.M.2    Lykkesfeldt, A.E.3    Dell'Orto, P.4    Del Curto, B.5    Henriksen, K.L.6
  • 32
    • 73949105921 scopus 로고    scopus 로고
    • Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2ñpositive, hormone receptorñpositive metastatic breast cancer: Results from the randomized phase III TAnDEM Study
    • Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A,Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2ñpositive, hormone receptorñpositive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. J Clin Oncol. 2009;27(33):5529.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5529
    • Kaufman, B.1    Mackey, J.R.2    Clemens, M.R.3    Bapsy, P.P.4    Vaid, A.5    Wardley, A.6
  • 33
    • 73149115341 scopus 로고    scopus 로고
    • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorñpositive metastatic breast cancer
    • Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorñpositive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538.
    • (2009) J Clin Oncol , vol.27 , Issue.33 , pp. 5538
    • Johnston, S.1    Pippen, J.2    Pivot, X.3    Lichinitser, M.4    Sadeghi, S.5    Dieras, V.6
  • 34
    • 77649173208 scopus 로고    scopus 로고
    • Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance
    • Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res. 2010;16(5):1486.
    • (2010) Clin Cancer Res , vol.16 , Issue.5 , pp. 1486
    • Leary, A.F.1    Drury, S.2    Detre, S.3    Pancholi, S.4    Lykkesfeldt, A.E.5    Martin, L.A.6
  • 35
    • 13844273087 scopus 로고    scopus 로고
    • PI3K-Akt pathway: Its functions and alterations in human cancer
    • DOI 10.1023/B:APPT.0000045801.15585.dd
    • Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667-76. (Pubitemid 40941196)
    • (2004) Apoptosis , vol.9 , Issue.6 , pp. 667-676
    • Osaki, M.1    Oshimura, M.2    Ito, H.3
  • 36
    • 32944457518 scopus 로고    scopus 로고
    • mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500.
    • (2006) Cancer Res , vol.66 , Issue.3 , pp. 1500
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.B.3    Solit, D.4    Mills, G.B.5    Smith, D.6
  • 38
    • 0034920457 scopus 로고    scopus 로고
    • Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer
    • DOI 10.1038/modpathol.3880371
    • Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001;14(7):672-6. (Pubitemid 32667211)
    • (2001) Modern Pathology , vol.14 , Issue.7 , pp. 672-676
    • Depowski, P.L.1    Rosenthal, S.I.2    Ross, J.S.3
  • 39
    • 0034790016 scopus 로고    scopus 로고
    • mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
    • Yu K, Toral-Barza L, Discafani C, Zhang W, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine Relat Canc. 2001;8(3):249.
    • (2001) Endocrine Relat Canc , vol.8 , Issue.3 , pp. 249
    • Yu, K.1    Toral-Barza, L.2    Discafani, C.3    Zhang, W.4    Skotnicki, J.5    Frost, P.6
  • 40
    • 79959508436 scopus 로고    scopus 로고
    • Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
    • Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011;16(Supplement 1):12.
    • (2011) Oncologist , vol.16 , Issue.SUPPL. 1 , pp. 12
    • Baselga, J.1
  • 42
    • 65549167833 scopus 로고    scopus 로고
    • Targeting the mTOR signaling network for cancer therapy
    • Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278.
    • (2009) J Clin Oncol , vol.27 , Issue.13 , pp. 2278
    • Meric-Bernstam, F.1    Gonzalez-Angulo, A.M.2
  • 43
    • 66849136781 scopus 로고    scopus 로고
    • Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptorñpositive breast cancer
    • Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptorñpositive breast cancer. J Clin Oncol. 2009;27(16):2630.
    • (2009) J Clin Oncol , vol.27 , Issue.16 , pp. 2630
    • Baselga, J.1    Semiglazov, V.2    Van Dam, P.3    Manikhas, A.4    Bellet, M.5    Mayordomo, J.6
  • 44
    • 84858708683 scopus 로고    scopus 로고
    • Exploratory subgroup analysis of the TAMRAD phase 2 GINECO trial comparing tamoxifen (TAM) plus everolimus (RAD) with TAM alone in patients with Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) with prior exposure to aromatase inhibitors (AIs): Implication for research strategies
    • Program and abstracts of the This abstract reports the results of the BOLERO-2 phase III trial
    • Bourgier C, Ray-Coquard I, J. P, editors. Exploratory subgroup analysis of the TAMRAD phase 2 GINECO trial comparing tamoxifen (TAM) plus everolimus (RAD) with TAM alone in patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) with prior exposure to aromatase inhibitors (AIs): implication for research strategies. Program and abstracts of the 2011 European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden. This abstract reports the results of the BOLERO-2 phase III trial.
    • 2011 European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden
    • Bourgier, C.1    Ray-Coquard, I.J.P.2
  • 45
    • 84858701497 scopus 로고    scopus 로고
    • Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: Results of the BOLERO-2 phase III trial
    • Program and abstracts of the This is about the management of adverse events associated with the use of everolimus in advanced renal cell carcinoma, but it is useful for the breast cancer oncologist who wants to know more about the side effect profile of everolimus
    • Baselga J, Campone M, Piccart-Gebhart J, editors. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: results of the BOLERO-2 phase III trial. Program and abstracts of the 2011 European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden. This is about the management of adverse events associated with the use of everolimus in advanced renal cell carcinoma, but it is useful for the breast cancer oncologist who wants to know more about the side effect profile of everolimus.
    • 2011 European Multidisciplinary Cancer Congress; 2011 September 23-27; Stockholm, Sweden
    • Baselga, J.1    Campone, M.2    Piccart-Gebhart, J.3
  • 46
    • 79957566962 scopus 로고    scopus 로고
    • Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
    • Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Canc. 2011.
    • (2011) Eur J Canc
    • Porta, C.1    Osanto, S.2    Ravaud, A.3    Climent, M.A.4    Vaishampayan, U.5    White, D.A.6
  • 47
    • 57149137029 scopus 로고    scopus 로고
    • Crosstalk between IGF1R and estrogen receptor signaling in breast cancer
    • doi:10.1007/s10911-008-9098-0
    • Fagan D, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13(4):423-9. doi:10.1007/s10911-008-9098-0.
    • (2008) J Mammary Gland Biol Neoplasia , vol.13 , Issue.4 , pp. 423-429
    • Fagan, D.1    Yee, D.2
  • 48
    • 80053932300 scopus 로고    scopus 로고
    • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14
    • doi:10.1200/ jco.2010.33.7006
    • Pritchard KI, Shepherd LE, Chapman J-AW, Norris BD, Cantin J, Goss PE, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29(29):3869-76. doi:10.1200/ jco.2010.33.7006.
    • (2011) J Clin Oncol , vol.29 , Issue.29 , pp. 3869-3876
    • Pritchard, K.I.1    Shepherd, L.E.2    Chapman, J.-A.W.3    Norris, B.D.4    Cantin, J.5    Goss, P.E.6
  • 49
    • 80053956239 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor pathway in estrogen receptor positive breast cancer: A bumpy start with an uncertain future
    • doi:10.1200/ jco.2011.36.6393
    • Dickler MN. Targeting the insulin-like growth factor pathway in estrogen receptor positive breast cancer: a bumpy start with an uncertain future. J Clin Oncol. 2011;29(29):3846-8. doi:10.1200/ jco.2011.36.6393.
    • (2011) J Clin Oncol , vol.29 , Issue.29 , pp. 3846-3848
    • Dickler, M.N.1
  • 50
    • 77955883504 scopus 로고    scopus 로고
    • A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)
    • O' Shaughnessy J, Miles D, Gray R, Dieras V, Perez E, Zon R, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010;28(15 suppl):1005.
    • (2010) J Clin Oncol , vol.28 , Issue.15 SUPPL. , pp. 1005
    • O'Shaughnessy, J.1    Miles, D.2    Gray, R.3    Dieras, V.4    Perez, E.5    Zon, R.6
  • 51
    • 77449129151 scopus 로고    scopus 로고
    • Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    • doi:10.1200/jco.2009.21.8784
    • Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010;28 (4):628-33. doi:10.1200/jco. 2009.21.8784.
    • (2010) J Clin Oncol , vol.28 , Issue.4 , pp. 628-633
    • Traina, T.A.1    Rugo, H.S.2    Caravelli, J.F.3    Patil, S.4    Yeh, B.5    Melisko, M.E.6
  • 52
    • 79960371728 scopus 로고    scopus 로고
    • Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer
    • Roberts CG, Millar EKA, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene. 2011;30 (28):3186-97.
    • (2011) Oncogene , vol.30 , Issue.28 , pp. 3186-3197
    • Roberts, C.G.1    Millar, E.K.A.2    O'Toole, S.A.3    McNeil, C.M.4    Lehrbach, G.M.5    Pinese, M.6
  • 53
    • 80052009896 scopus 로고    scopus 로고
    • Epigenetic modulation: A novel therapeutic target for overcoming hormonal therapy resistance
    • Raha P, Thomas S, Munster PN. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011;3(4):451-70.
    • (2011) Epigenomics , vol.3 , Issue.4 , pp. 451-470
    • Raha, P.1    Thomas, S.2    Munster, P.N.3
  • 55
    • 79958084461 scopus 로고    scopus 로고
    • A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
    • Munster P, Thurn K, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104 (12):1828-35.
    • (2011) Br J Cancer , vol.104 , Issue.12 , pp. 1828-1835
    • Munster, P.1    Thurn, K.2    Thomas, S.3    Raha, P.4    Lacevic, M.5    Miller, A.6
  • 58
    • 78650517428 scopus 로고    scopus 로고
    • p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
    • Fernandez-Cuesta L, Anaganti S, Hainaut, Olivier. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Canc. 2010.
    • (2010) Int J Canc
    • Fernandez-Cuesta, L.1    Anaganti, S.H.2    Olivier3
  • 59
    • 79960732694 scopus 로고    scopus 로고
    • PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
    • Weigelt B, Warne P, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene. 2011.
    • (2011) Oncogene
    • Weigelt, B.1    Warne, P.2    Downward, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.